Xembify, a 20% concentration SCIg product supplied by Grifols Australia, will be available for supply under the national blood arrangements from January 2024.
The Therapeutic Goods Administration (TGA) recently approved a submission from the Australian Red Cross Lifeblood (Lifeblood) to reduce the deferral period for
The Therapeutic Goods Administration (TGA) approved submissions from the Australian Red Cross Lifeblood (Lifeblood) to remove the deferral period for donors who
We developed the Criteria for the clinical use of immunoglobulin in Australia (the Criteria) using specialist working groups of expert clinicians to identify th
